Aberrant fucosylation sustains the NOTCH and EGFR/NF-?B pathways and has a prognostic value in human intrahepatic cholangiocarcinoma

Article Pharmacology & Pharmacy

Inhibition of fucosylation by 2-fluorofucose attenuated acetaminophen-induced liver injury via its anti-inflammation and anti-oxidative stress effects

Zhaoguo Liu et al.

Summary: 2FF can inhibit fucosylation and alleviate APAP-induced acute liver injury. It relieves oxidative stress and mitochondria damage, enhances Nrf2 nuclear translocation, and suppresses the expression of inflammation-associated proteins.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Fluorinated rhamnosides inhibit cellular fucosylation

Johan F. A. Pijnenborg et al.

Summary: A class of fucosylation metabolic prodrug inhibitors have been developed and shown to inhibit cellular fucosylation effectively. This research is crucial for understanding the biological role of fucose sugars and developing potential therapeutics to treat diseases associated with aberrant expression of fucosylated glycans.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations

Silvia Affo et al.

Summary: The study reveals that hepatic stellate cells (HSC) are the main source of cancer-associated fibroblasts (CAF), and HSC-derived CAF interact predominantly with tumor cells. In mouse models, CAF promote the progression of intrahepatic cholangiocarcinoma (ICC), while in patients, a high pan-CAF signature is associated with decreased survival and increased recurrence. Single-cell RNA sequencing segregates CAF into distinct subpopulations, with different interactions with tumor cells and promoting ICC growth.

CANCER CELL (2021)

添加到收藏夹

Review Oncology

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting

Massimiliano Salati et al.

Summary: Intrahepatic cholangiocarcinoma (iCCA) is a distinct entity with rising incidence and poor prognosis. Gene fusions involving FGFR2 have shown unprecedented efficacy in nearly 50% of cases, leading to FDA approval of two oral selective FGFR2 targeted agents. Clinical trials are underway to test targeted approach against standard chemotherapy, while translational studies aim to optimize FGFR2 blockade in iCCA.

CANCER MANAGEMENT AND RESEARCH (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.

Elena Lopez Miranda et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment

Chengcheng Liao et al.

Summary: The research highlights the association between FUT8 and core fucosylation in various tumors, suggesting their potential as markers for cancer diagnosis and prognosis, as well as providing potential targets for tumor therapy. Additionally, defucosylation of IGg1 antibodies may enhance antibody affinity, presenting another avenue for tumor therapy utilizing FUT8.

JOURNAL OF CANCER (2021)

添加到收藏夹

Article Gastroenterology & Hepatology